Physician Survey Demonstrates Need for Greater Awareness of Rare, Life-Threatening Lung Condition
A new survey sponsored by Bayer revealed that many physicians report a lack of familiarity with chronic thromboembolic pulmonary hypertension (CTEPH). The survey was released on November 24 to bring attention to the condition and the need for further education to improve the patient pathway to diagnosis and effective treatment.
CTEPH is a rare, life-threatening form of pulmonary hypertension (PH) that causes high blood pressure in the lungs and can lead to right heart failure and death. Each year, in the US, about 600,000 persons have an acute pulmonary embolism, and it is estimated that there are between 500 and 2500 new cases of CTEPH diagnosed each year. The incidence and prevalence of CTEPH are yet to be accurately determined and may be significantly underestimated. In fact, as many as 1 out of every 25 people who had a pulmonary embolism (even if they were treated with at least 3 months of anticoagulants), go on to develop CTEPH.*
“Because surgery can be an effective treatment for CTEPH, it is critical that physicians suspect and diagnose the condition. Unfortunately, as demonstrated by this survey, recognition of CTEPH among primary care physicians is inadequate,” said Richard Channick, M.D., director of Massachusetts General Hospital’s Pulmonary Hypertension and Thromboendarterectomy Program. “We very much need further education to identify and treat these patients as quickly as possible.”
Read more about the survey here...